Received: 14 June 2020
Accepted: 19 November 2020
First Online: 27 November 2020
Ethics approval and consent to participate
: The study was approved by the local Ethical Committee (Campus Neurológico Sénior Ethical Committee, reference number 05–2020) and complied with national legislation and the Declaration of Helsinki guidelines. Imaging and clinical data were retrospectively collected, so the need for individual consent was waived.
: Not applicable.
: RMS has no conflict of interest relevant to this work but is currently a consultant for BIAL – PORTELA & C.a, S.A. and has been a consultant for Zambon and AbbVie.JJF has no conflict of interest relevant to this work but reports having received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic. He received consultancy fees from GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals. He is employed by Faculdade de Medicina de Lisboa and CNS - Campus Neurológico Sénior. He also participated in advisory boards for Bial and expert testimony to Novartis.MF has no conflict of interest relevant to this work but received honoraria to speak from AbbVie.Remaining authors have no conflict of interest nor relevant disclosures for the past 12 months.